EGFR and glioblastoma: Targeting EGFR in glioblastoma patients with tyrosine kinase inhibitors used for the treatment of EGFR-mutated lung cancer has not shown convincing efficacy, likely because of the lack of sensitizing mutations and intratumoral heterogeneity of EGFR expression.13